Kidney Disease

Nephrology·MeSH: Kidney Diseases

Prevalence

15000.0 / 100K

Incidence

500.0 / 100K/yr

80 drugs in development·44 companies·6 clinical trials

Drug Pipeline by Phase

Approved(13)

Drug	Company
cinacalcet	DR REDDYS LABORATORIES LTD (RDY)
doxercalciferol	Amneal Pharmaceuticals, Inc. (AMRX)
EVRENZO (爱瑞卓®) / roxadustat	KYNTRA BIO INC. (KYNB)
inpefa	LEXICON PHARMACEUTICALS, INC. (LXRX)
Jardiance	ELI LILLY & Co (LLY)
Jardiance®	ELI LILLY & Co (LLY)
korsuva / kapruvia	Tvardi Therapeutics, Inc. (TVRD)
rayaldee	REPLIGEN CORP (RGEN)
rayaldee	OPKO HEALTH, INC. (OPK)
sevelamer carbonate	DR REDDYS LABORATORIES LTD (RDY)
sevelamer carbonate	Impax Laboratories, LLC (IPXL)
Vafseo	Akebia Therapeutics, Inc. (AKBA)
XPHOZAH	ARDELYX, INC. (ARDX)

Phase 3(19)

Drug	Company
Auryxia	Akebia Therapeutics, Inc. (AKBA)
AZD4248	ASTRAZENECA PLC (AZN)
bardoxolone	REATA PHARMACEUTICALS INC (RETA)
ctap101	OPKO HEALTH, INC. (OPK)
Empagliflozin	Valneva SE (VALN)
erythropoiesis stimulating agent	GH Research PLC (GHRS)
Erythropoiesis-Stimulating Agent	Akebia Therapeutics, Inc. (AKBA)
ferric	KERYX BIOPHARMACEUTICALS INC (KERYX)
ferric citrate	Akebia Therapeutics, Inc. (AKBA)
ferumoxytol	AMAG PHARMACEUTICALS, INC. (AMAG)
mezagitamab	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
mezagitamab	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Mezagitamab	Crinetics Pharmaceuticals, Inc. (CRNX)
ravulizumab	Hepion Pharmaceuticals, Inc. (CTRVP)
Vadadustat	Akebia Therapeutics, Inc. (AKBA)
venglustat gz402671	Sanofi (SNY)
veverimer	Tricida, Inc. (TCDA)
zigakibart	Novartis AG (NVS)
ziltivekimab	Novo Nordisk A/S (NVO)

Phase 2(17)

Drug	Company
2hpβcd	ZyVersa Therapeutics, Inc. (ZVSA)
AKB-097	Akebia Therapeutics, Inc. (AKBA)
aln-ang3	REGENERON PHARMACEUTICALS, INC. (REGN)
aln-ang3	West Pharmaceutical Services Inc. (WST)
cin-107	CinCor Pharma, Inc. (CINC)
erepoxen	Xenetic Biosciences, Inc. (XBIO)
evinacumab	REGENERON PHARMACEUTICALS, INC. (REGN)
evinacumab	West Pharmaceutical Services Inc. (WST)
inaxaplin	VERTEX PHARMACEUTICALS INC / MA (VRTX)
lorundrostat 25mg+sglt2i qd	Mineralys Therapeutics, Inc. (MLYS)
mze782	Maze Therapeutics, Inc. (MAZE)
mze829	Maze Therapeutics, Inc. (MAZE)
renal autologous cell therapy	PROKIDNEY CORP. (PROK)
tour006	Tourmaline Bio, Inc. (TRML)
tour006 -	Tourmaline Bio, Inc. (TRML)
vx-147	VERTEX PHARMACEUTICALS INC / MA (VRTX)
zigakibart	Novartis AG (NVS)

Phase 1(15)

Drug	Company
azd1613 - part a	ASTRAZENECA PLC (AZN)
azd1613 - part b	ASTRAZENECA PLC (AZN)
disc-0974	Disc Medicine, Inc. (IRON)
drsp/ee	VERTEX PHARMACEUTICALS INC / MA (VRTX)
farabursen	Regulus Therapeutics Inc. (RGLS)
lng/ee	VERTEX PHARMACEUTICALS INC / MA (VRTX)
LY3841136	ELI LILLY & Co (LLY)
net/ee	VERTEX PHARMACEUTICALS INC / MA (VRTX)
ngm/ee	VERTEX PHARMACEUTICALS INC / MA (VRTX)
nnc0519-0130	Novo Nordisk A/S (NVO)
ojr520	NOVARTIS AG (NVSEF)
ojr520	Novartis AG (NVS)
rgls8429	Regulus Therapeutics Inc. (RGLS)
vonsetamig	REGENERON PHARMACEUTICALS, INC. (REGN)
vx-407	VERTEX PHARMACEUTICALS INC / MA (VRTX)

Preclinical(8)

Drug	Company
electroceuticals therapeutic devices	ENDONOVO THERAPEUTICS, INC. (ENDV)
ergod2	ENTIA BIOSCIENCES, INC. (ERGO)
matloc 1	MARIZYME, INC. (MRZM)
matloc 2	MARIZYME, INC. (MRZM)
pulsevet shock wave therapy	Zomedica Corp. (ZOMDF)
RDX020	ARDELYX, INC. (ARDX)
react/gen	PROKIDNEY CORP. (PROK)
react/universal	PROKIDNEY CORP. (PROK)

Unknown(1)

Drug	Company
noninterventional	REGENERON PHARMACEUTICALS, INC. (REGN)

Phase 1/Phase 2(1)

Drug	Company
80-ppm no	GH Research PLC (GHRS)

Phase 2/Phase 3(1)

Drug	Company
tecarfarin	Cadrenal Therapeutics, Inc. (CVKD)

Phase 4(5)

Drug	Company
Baxdrostat/dapagliflozin	ASTRAZENECA PLC (AZN)
Dapagliflozin 10mg Tab	ASTRAZENECA PLC (AZN)
empagliflozin	ENANTA PHARMACEUTICALS INC (ENTA)
sham treatment	GH Research PLC (GHRS)
Zibotentan/Dapagliflozin	ASTRAZENECA PLC (AZN)

BioSniper tracks 80 drugs in development for Kidney Disease across 44 companies.

There are 6 clinical trials targeting Kidney Disease tracked by BioSniper.

The estimated prevalence of Kidney Disease is approximately 15000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.